Ranking Alexa Global: # 1,134,936,Alexa Ranking in United Kingdom is # 53,804
Server:cloudflare...
The main IP address: 54.217.205.97,Your server Ireland,Dublin ISP:Amazon.com Inc. TLD:uk CountryCode:IE
The description :navigation content footer uk novartis site directory search our work clinical trials manufacturing disease areas novartis in the uk about us the novartis group who we are corporate responsibility our...
This report updates in 28-Jul-2018
Created Date: | 23-Apr-1997 |
Changed Date: | 22-Mar-2018 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host novartis.co.uk. Currently, hosted in Ireland and its service provider is Amazon.com Inc. .
Latitude: | 53.343990325928 |
Longitude: | -6.2671899795532 |
Country: | Ireland (IE) |
City: | Dublin |
Region: | Dublin City |
ISP: | Amazon.com Inc. |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called cloudflare containing the details of what the browser wants and will accept back from the web server.
Expect-CT: | max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct" |
X-Request-ID: | 3d692b8812ed1c09654f98fcd4ea8d65 |
X-Drupal-Cache: | HIT |
Content-Language: | en |
X-Content-Type-Options: | nosniff |
Content-Encoding: | gzip |
Transfer-Encoding: | chunked |
Set-Cookie: | __cfduid=da1846151d7ff42c45f1c75e7ad7b401e1532727132; expires=Sat, 27-Jul-19 21:32:12 GMT; path=/; domain=.novartis.co.uk; HttpOnly |
CF-Cache-Status: | HIT |
Expires: | Sat, 28 Jul 2018 03:32:12 GMT |
X-AH-Environment: | prod |
Server: | cloudflare |
Last-Modified: | Fri, 27 Jul 2018 20:25:46 GMT |
Connection: | keep-alive |
Link: | |
X-UA-Compatible: | IE=edge,chrome=1 |
Cache-Control: | public, max-age=21600 |
Date: | Fri, 27 Jul 2018 21:32:12 GMT |
X-Frame-Options: | SAMEORIGIN |
Content-Type: | text/html; charset=utf-8 |
CF-RAY: | 441237a41fc891d6-EWR |
soa: | dns1.novartis.com. hostmaster.novartis.com. 2018060401 28800 7200 604800 3600 |
txt: | "Order 00721368 [email protected]" "a52541c3401c4737bbad3216be6b9a1d" "v=spf1 mx a" |
ns: | dns1.novartis.com. mia03-1.digex.com. dns2.novartis.com. |
ipv4: | IP:54.217.205.97 ASN:16509 OWNER:AMAZON-02 - Amazon.com, Inc., US Country:US |
navigation content footer uk novartis site directory search our work clinical trials manufacturing disease areas novartis in the uk about us the novartis group who we are corporate responsibility our commitment to patients and caregivers contact us partnerships with the nhs with patient groups patient resources grants and sponsorships access to healthcare news uk news and media releases media library annual report novartis world news press office careers career search working at novartis future talent programme graduate recruitment homepage at novartis, we are reimagining medicine the extraordinary need for an ordinary life novartisuk colleagues share their personal healthcare challenges in a new campaign #novartisiswithyou read the story nhs70 reflections from our managing director and country president, haseeb ahmad read the story collaborates with buckinghamshire healthcare nhs trust to improve patients’ experience read about the collaboration between and buckinghamshire healthcare nhs trust... read more community partnership day 2018 our community partnership day is a very special day in the novartis calendar. read more , a top employer 2018 hear from erica cassin, hr director at , on what winning uk and europe top employer... read more navigate novartis the novartis group uk news and media releases careers partnerships media releases nice recommends novartis’ rydapt® (midostaurin)▼ for patients with newly diagnosed flt3-mutated aml, the first new treatment in more than 25 years1,2 novartis presents first-of-its-kind data at aan for aimovigtm* (erenumab) in migraine patients that have failed multiple prior preventive treatments novartis to present new interim data on the impact of immune thrombocytopenia (itp) on uk patients’ physical and emotional wellbeing data published in the lancet show novartis siponimod significantly delays disability progression in patients with secondary progressive ms read more @novartisuk 10 hours 17 min ago rt @nhschoices: we're likely to see very high temperatures again today. try to avoid excess alcohol and caffeine. more advice here:… https://t.co/jvlmbyrxvz follow us who we are novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes. learn more corporate brochure find out more about our large and diverse organisation in our corporate brochure learn more our work about us partnerships news careers locations contact us modern slavery statement subscribe to novartis facebook twitter linkedin novartis site directory © 2018 novartis ag this site is intended for an audience in the united kingdom terms of use privacy policy about cookies accessibility modern slavery statement
https://www.novartis.co.uk/news/uk-news-and-media-releases?type=all
https://www.novartis.co.uk/stories/hope/extraordinary-need-ordinary-life
https://www.novartis.co.uk/stories/global-impact/novartis-uk-celebrates-22nd-community-partnership-day-2018
https://www.novartis.co.uk/our-work/novartis-uk
https://www.novartis.co.uk/about-us
https://www.novartis.co.uk/partnerships/patient-resources
https://www.novartis.co.uk/our-work/clinical-trials
https://www.novartis.co.uk/stories/hope/novartis-uk-collaborates-buckinghamshire-healthcare-nhs-trust-improve-patients
https://www.novartis.co.uk/about-us/contact-us
https://www.novartis.co.uk/about-us/contact-us/novartis-site-directory
https://www.novartis.co.uk/#footer
https://www.novartis.co.uk/#
https://www.novartis.co.uk/privacy-policy
https://www.novartis.co.uk/careers
https://www.novartis.co.uk/partnerships/grants-which-includes-medical-educational-goods-and-services-megs
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain name:
novartis.co.uk
Data validation:
Nominet was not able to match the registrant's name and/or address against a 3rd party source on 10-Jun-2014
Registrar:
Markmonitor Inc. t/a MarkMonitor Inc. [Tag = MARKMONITOR]
URL: http://www.markmonitor.com
Relevant dates:
Registered on: 23-Apr-1997
Expiry date: 23-Apr-2020
Last updated: 22-Mar-2018
Registration status:
Registered until expiry date.
Name servers:
dns1.novartis.com
dns2.novartis.com
mia03.digex.com
WHOIS lookup made at 22:32:14 27-Jul-2018
--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REFERRER http://www.nominet.org.uk
REGISTRAR Nominet UK
SERVERS
SERVER co.uk.whois-servers.net
ARGS novartis.co.uk
PORT 43
TYPE domain
DOMAIN
SPONSOR
Markmonitor Inc. t/a MarkMonitor Inc. [Tag = MARKMONITOR]
URL: http://www.markmonitor.com
Relevant dates:
CREATED 23-Apr-1997
CHANGED 22-Mar-2018
STATUS
Registered until expiry date.
NSERVER
DNS1.NOVARTIS.COM 160.62.4.7
DNS2.NOVARTIS.COM 160.62.7.59
MIA03.DIGEX.COM 216.255.129.246
NAME novartis.co.uk
DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REGISTERED no
The following list shows you to spelling mistakes possible of the internet users for the website searched .